BackAllergy Therapeutics plc Overview

Allergy Therapeutics plc Current Assets

Track Allergy Therapeutics plc's current assets ($36M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$36.25M
↓ 14.03% YoYΔ $-5.91M vs prior year quarter

Peer trimmed avg / median

Loading

Allergy Therapeutics plc Current Assets History

Loading

Allergy Therapeutics plc vs. peers: Current Assets Comparison

Loading

Allergy Therapeutics plc Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Allergy Therapeutics plc (AGYTF) FAQ

Allergy Therapeutics plc posts a current assets of $36M as of December 2025. That compares with $42M in the prior-year period — down 14.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Allergy Therapeutics plc's current assets was $42M. The latest reading is $36M — a 14.0% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Allergy Therapeutics plc's financial statement story. At $36M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AGYTF's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Allergy Therapeutics plc's other metric pages and overview cover the third.